United Therapeutics CEO Martine Rothblatt sells $4.96 million in stock By Investing.com

Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp (), sold 9,500 shares of the company’s common stock on July 29, 2026, for a total value of $4,962,487. The shares were sold at prices ranging from $517.68 to $525.78 per share. This transaction followed the exercise of 9,500 stock options, which were acquired at an exercise price of $135.42 per share, totaling $1,286,489. The sale comes after an impressive 86% return over the past year, with the stock currently trading at $524.70.

Both the option exercise and subsequent sale of common stock were conducted under a pre-arranged 10b5-1 trading plan, which Rothblatt adopted on November 7, 2025. The shares and stock options involved in these transactions are held indirectly by family trusts, where Rothblatt shares investment power and is a beneficiary along with immediate family members.

Following these transactions, Rothblatt indirectly holds 324,443 shares of common stock in various family trusts, along with 246,410 stock options. According to InvestingPro analysis, UTHR currently appears overvalued relative to its Fair Value, though the company maintains a “GREAT” financial health score. Investors seeking deeper insights can access the comprehensive Pro Research Report, available for UTHR and 1,400+ other US stocks.

In other recent news, United Therapeutics Corporation received premarket approval from the U.S. Food and Drug Administration for its LungFX device, which is designed for centralized ex vivo lung perfusion. This device aims to assess donor lungs outside the body after procurement and before transplantation. Additionally, TD Cowen reiterated a Buy rating on United Therapeutics stock, maintaining a price target of $675.00. Meanwhile, BETA Technologies successfully completed the first electric conventional takeoff and landing aircraft flights under the FAA’s eVTOL Integration Pilot Program. These flights were conducted in collaboration with various state aviation departments and covered approximately 275 nautical miles across Virginia and Maryland. In the biopharmaceutical sector, Raymond James issued an earnings preview for Insmed, suggesting potential for sequential launch growth that could exceed 2026 consensus expectations. These developments highlight significant progress and strategic initiatives across various sectors.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.